Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Published:2013-12 Issue:12 Volume:24 Page:2978-2984
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gerber B.,Loibl S.,Eidtmann H.,Rezai M.,Fasching P.A.,Tesch H.,Eggemann H.,Schrader I.,Kittel K.,Hanusch C.,Kreienberg R.,Solbach C.,Jackisch C.,Kunz G.,Blohmer J.U.,Huober J.,Hauschild M.,Nekljudova V.,Untch M.,von Minckwitz G.

Funder

Amgen and Novartis

Roche

Roche and Sanofi-Aventis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/12/2978/408439/mdt361.pdf

Reference26 articles.

1. Time-trends in survival in young women with breast cancer in a SEER population-based study;Ademuyiwa;Breast Cancer Res Treat,2013

2. Triple-negative breast cancer: role of antiangiogenic agents;Greenberg;Cancer J,2010

3. Vascular proliferation is increased in basal-like breast cancer;Nalwoga;Breast Cancer Res Treat,2011

4. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival;Chang;Proc Natl Acad Sci USA,2005

5. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer;Linderholm;Ann Oncol,2009

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer;2024-06-26

2. Exploring the Potential of Nanomolecular Therapeutic Therapy Options, and Novel Biomarkers in Triple-negative Breast Cancer Treatment;Current Cancer Therapy Reviews;2024-06-11

3. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials;Clinical Cancer Research;2024-06-05

4. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial;eClinicalMedicine;2024-05

5. A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC);Journal of Nanoparticle Research;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3